BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction | MicrobiomeTrials← Back to trialsNCT02876042
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
CompletedOBSERVATIONAL
Trial Details
Start: 2017-03-23Est. Completion: 2025-11-03
Enrollment target: 11 participants Locations- Berlin Charité & Deutschen Herzzentrum Berlin, Berlin, Germany
- Immanuel Klinikum Bernau Herzzentrum Brandenburg, Bernau, Germany
- Universitätsklinikum Köln Herzzentrum, Cologne, Germany
- Lippe Klinikum, Detmold, Germany
- Uniklinik Frankfurt, Frankfurt, Germany
- Universitätsklinikum Gießen und Marburg, Giessen, Germany
- Herzzentrum Göttingen, Göttingen, Germany
- Asklepios Klinik Altona, Hamburg, Germany
- Medizinische Hochschule Hannover, Hanover, Germany
- Uniklinik Heidelberg, Heidelberg, Germany
- Kardiologie im Klinikum Ingolstadt, Ingolstadt, Germany
- Universitätsklinikum Regensburg, Regensburg, Germany
- Marienkrankenhaus Siegen, Siegen, Germany
Other microbiome trials you might be interested in
Heart Failure
The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in…
Hamburg, GermanyEst. completion Jul 2027
Low Grade AstrocytomaLow Grade GliomaMetastatic Low Grade AstrocytomaMetastatic Low Grade GliomaWHO Grade 1 GliomaWHO Grade 2 Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincr…
Birmingham, United StatesEst. completion Dec 31, 2030
Acute-On-Chronic Liver FailureSepsis
This study aims to evaluate the efficacy and safety of the double plasma cytokine adsorption system with sequential low-…
Guangzhou, ChinaEst. completion Oct 31, 2027